Masters AR - Search Results

1

Characterization of the Stereoselective Disposition of Bupropion and Its Metabolites in Rat Plasma and Brain.

Bhattacharya CS, Masters AR, Bach C, Sinn AL, Trowbridge MA, Stratford RE Jr. Bhattacharya CS, et al. Among authors: masters ar. Eur J Drug Metab Pharmacokinet. 2023 Mar;48(2):171-187. doi: 10.1007/s13318-023-00817-9. Epub 2023 Feb 23. Eur J Drug Metab Pharmacokinet. 2023. PMID: 36823342

2

Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Masters AR, Gufford BT, Lu JB, Metzger IF, Jones DR, Desta Z. Masters AR, et al. J Pharmacol Exp Ther. 2016 Aug;358(2):230-8. doi: 10.1124/jpet.116.232876. Epub 2016 Jun 2. J Pharmacol Exp Ther. 2016. PMID: 27255113 Free PMC article. Clinical Trial.

3

Population model analysis of chiral inversion and degradation of bupropion enantiomers, and application to enantiomer specific fraction unbound determination in rat plasma and brain.

Bhattacharya C, Masters AR, Bach C, Stratford RE Jr. Bhattacharya C, et al. Among authors: masters ar. J Pharm Biomed Anal. 2021 Feb 20;195:113872. doi: 10.1016/j.jpba.2020.113872. Epub 2020 Dec 26. J Pharm Biomed Anal. 2021. PMID: 33388643 Free PMC article.

4

Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.

Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, Schneider BP, Storniolo AM, Bauchle A, Althouse SK, Perkins SM, Masters AR, Stratford RE Jr, Dong Z, Liu JY, Zhang JT, Miller KD. Sardesai SD, et al. Among authors: masters ar. Clin Cancer Res. 2021 Nov 1;27(21):5810-5817. doi: 10.1158/1078-0432.CCR-21-0493. Epub 2021 Aug 16. Clin Cancer Res. 2021. PMID: 34400413 Clinical Trial.

5

Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.

Masters AR, McCoy M, Jones DR, Desta Z. Masters AR, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Mar 15;1015-1016:201-208. doi: 10.1016/j.jchromb.2016.02.018. Epub 2016 Feb 18. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 26946423 Free PMC article.

6

Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers.

Gufford BT, Metzger IF, Bamfo NO, Benson EA, Masters AR, Lu JBL, Desta Z. Gufford BT, et al. Among authors: masters ar. J Pharmacol Exp Ther. 2022 Jul 7;382(3):313-26. doi: 10.1124/jpet.122.001277. Online ahead of print. J Pharmacol Exp Ther. 2022. PMID: 35798386 Free PMC article.

7

Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.

Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Ogburn ET, et al. Among authors: masters ar. Drug Metab Dispos. 2010 Jul;38(7):1218-29. doi: 10.1124/dmd.109.031393. Epub 2010 Mar 24. Drug Metab Dispos. 2010. PMID: 20335270 Free PMC article.

8

Stereoselective Analysis of Methadone and EDDP in Laboring Women and Neonates in Plasma and Dried Blood Spots and Association with Neonatal Abstinence Syndrome.

Metzger IF, Thomas AE, Evrard CA, Jones DR, Masters AR, Haas DM, Haneline LS, Quinney SK. Metzger IF, et al. Among authors: masters ar. Am J Perinatol. 2021 Jul;38(9):968-975. doi: 10.1055/s-0040-1701505. Epub 2020 Feb 12. Am J Perinatol. 2021. PMID: 32052397 Free PMC article.

9

Pharmacokinetic modeling of R and S-Methadone and their metabolites to study the effects of various covariates in post-operative children.

Aruldhas BW, Quinney SK, Overholser BR, Heathman MA, Masters AR, Ly RC, Gao H, Packiasabapathy S, Sadhasivam S. Aruldhas BW, et al. Among authors: masters ar. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1183-1194. doi: 10.1002/psp4.12687. Epub 2021 Aug 26. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34435753 Free PMC article.

10

SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease.

Jesudason CD, Mason ER, Chu S, Oblak AL, Javens-Wolfe J, Moussaif M, Durst G, Hipskind P, Beck DE, Dong J, Amarasinghe O, Zhang ZY, Hamdani AK, Singhal K, Mesecar AD, Souza S, Jacobson M, Salvo JD, Soni DM, Kandasamy M, Masters AR, Quinney SK, Doolen S, Huhe H, Rizzo SJS, Lamb BT, Palkowitz AD, Richardson TI. Jesudason CD, et al. Among authors: masters ar. Alzheimers Dement (N Y). 2023 Nov 17;9(4):e12429. doi: 10.1002/trc2.12429. eCollection 2023 Oct-Dec. Alzheimers Dement (N Y). 2023. PMID: 38023622 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32 results

Search Page